Immatics (NASDAQ:IMTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Immatics (NASDAQ:IMTX) from a sell rating to a hold rating in a report issued on Saturday.

Several other research firms have also recently commented on IMTX. Mizuho lifted their target price on shares of Immatics from $19.00 to $23.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Chardan Capital reiterated a “buy” rating and set a $25.00 price target on shares of Immatics in a report on Monday, November 24th. Zacks Research upgraded Immatics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a research report on Wednesday, October 8th. Finally, Guggenheim lifted their target price on Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.80.

Immatics Price Performance

IMTX opened at $9.75 on Friday. Immatics has a 1 year low of $3.30 and a 1 year high of $12.41. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -9.56 and a beta of 1.36. The firm’s fifty day moving average price is $10.13 and its two-hundred day moving average price is $8.03.

Immatics (NASDAQ:IMTX) last announced its earnings results on Monday, November 17th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.01. Immatics had a negative net margin of 146.13% and a negative return on equity of 24.16%. The company had revenue of $6.10 million during the quarter, compared to the consensus estimate of $12.53 million. As a group, equities analysts anticipate that Immatics will post -0.72 EPS for the current year.

Institutional Investors Weigh In On Immatics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vontobel Holding Ltd. bought a new position in Immatics during the second quarter worth about $59,000. Fox Run Management L.L.C. bought a new stake in shares of Immatics in the second quarter valued at approximately $136,000. Trexquant Investment LP purchased a new stake in shares of Immatics during the 1st quarter valued at approximately $783,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Immatics by 28.7% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock worth $172,000 after buying an additional 7,116 shares during the period. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Immatics in the 2nd quarter worth approximately $237,000. 64.41% of the stock is currently owned by institutional investors.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.